行情

SAGE

SAGE

SAGE
NASDAQ

实时行情|Nasdaq Last Sale

64.46
+4.28
+7.11%
盘后: 64.10 -0.36 -0.56% 19:56 12/06 EST
开盘
63.19
昨收
60.18
最高
65.90
最低
61.02
成交量
559.69万
成交额
--
52周最高
193.56
52周最低
56.50
市值
33.40亿
市盈率(TTM)
-4.7711
分时
5日
1月
3月
1年
5年

分析师评级

21位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SAGE 新闻

  • Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment
  • Benzinga.9小时前
  • Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment
  • Benzinga.9小时前
  • SunTrust Robinson Humphrey Downgrades Sage Therapeutics to Hold, Lowers Price Target to $70
  • Benzinga.13小时前
  • Benzinga's Top Upgrades, Downgrades For December 6, 2019
  • Benzinga.13小时前

更多

所属板块

生物技术和医学研究
+1.28%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

SAGE 简况

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
展开

Webull提供SAGE Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。